The warning letter Nanogen received last week from the US Food and Drug Administration will not affect approval of the company's NanoChip 400 System, and it is unlikely to alter the company's plan to offer the device into the same lab market to which it is accused of improperly marketing its Molecular Biology Workstation.

"This letter does not impact pre-market clearance work," Steve Gutman, director of the FDA Office of In Vitro Diagnostic Device Evaluation and Safety, wrote in an e-mail to Pharmacogenomics Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.